MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors

MapLight Therapeutics, Inc. (MPLT) announced an update on their ongoing clinical study.

MapLight Therapeutics Advances Mid-Stage Trial for Alzheimer’s Psychosis

The current Phase 2 study from MapLight Therapeutics (MPLT), officially titled “A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer’s Disease Psychosis,” aims to show whether its lead drug can safely reduce hallucinations and delusions in older adults with Alzheimer’s psychosis, a high-need area with limited treatment options and significant caregiver and payer burden.

The trial is testing ML-007C-MA, an oral drug candidate, against a placebo. The medicine is designed to ease hallucinations and delusions tied to Alzheimer’s disease psychosis, with the goal of improving behavior and daily function without the safety trade-offs often seen with older antipsychotic drugs.

The study uses a randomized design, meaning participants are assigned by chance to receive either ML-007C-MA or placebo. It is run in parallel groups, so each person stays in their assigned arm. It is “double-blind” for all key parties—patients, caregivers, study doctors, and outcome assessors—so no one knows who gets the active drug, helping limit bias. The main purpose is treatment-focused, looking at changes in psychosis symptoms using a standard clinical rating scale.

The trial was first submitted in March 2025, marking the formal start of regulatory tracking and public disclosure. The most recent update was filed on December 22, 2025, signaling that recruitment is active and the protocol remains current. Primary completion and overall completion dates are not yet reported, but investors should expect efficacy readouts to follow once enough patients finish treatment and assessments are locked for analysis.

For investors, this update reinforces that MapLight is moving its lead asset through a value-creating inflection point in an area where Big Pharma and biotech peers, such as companies developing Alzheimer’s therapies and neuropsychiatric drugs, are also competing. Positive future data could lift sentiment around MPLT by positioning ML-007C-MA as a differentiated option in Alzheimer’s psychosis, a segment with limited approved treatments. Conversely, trial setbacks could weigh on the stock given the program’s likely importance to MapLight’s pipeline. The ongoing progress may also draw strategic interest from larger players looking to add neuropsychiatric assets to complement emerging Alzheimer’s disease therapies. The study is currently recruiting and remains active, with further details and real-time updates available on the ClinicalTrials portal.

To learn more about MPLT’s potential, visit the MapLight Therapeutics, Inc. drug pipeline page.